Benzinga's Top #PreMarket Losers

Prima Biomed Ltd. PBMD shares tumbled 34.01 percent to $3.90 in pre-market trading following a 269.38 percent gain on Wednesday. NetApp Inc. NTAP fell 12.82 percent to $30.80 in pre-market trading after the company reported weaker-than-expected earnings for its fiscal fourth quarter on Wednesday. Analysts at Cantor Fitzgerald downgraded NetApp from Buy to Hold and lowered the price target from $43.00 to $35.00. Fate Therapeutics Inc FATE shares dropped 7.98 percent to $5.65 in pre-market after the company prices 6,000,000 shares of its common stock at $5.00 per share. Dicerna Pharmaceuticals Inc DRNA shares declined 5.03 percent to $17.75 in pre-market trading after the company priced a 2.75 million share offering at $17.75 per share. Sarepta Therapeutics Inc SRPT shares fell 4.23 percent to $25.13 in pre-market trading after jumping 60.20 percent on Wednesday. Bank of America downgraded Sarepta Therapeutics from Buy to Neutral and raised the price target from $20.00 to $28.00.